anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Hydroxychloroquine
Trial phase: Phase 1 | Phase 2
ATC code: P01BA02
SMILES: CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Subjects will receive HCQ plus standard of care TACE.

HCQ
Eligibility criteria:
Inclusion Criteria:

Patient capable of giving informed consent
Patient diagnosed with hepatocellular carcinoma in both lobes of the liver by one of the following methods (Pathologically confirmed HCC by biopsy or HCC 2 cm with classic radiographic findings of arterial phase enhancement with venous phase washout and pseudocapsule formation on contrast enhanced MRI or CT or Lesion greater than 2 cm with probable imaging features of HCC and imaging findings of cirrhosis and/or portal hypertension or a serum alphafetoprotein (AFP) greater than 200 mg/mL.
Patient not candidate for orthotopic liver transplantation at the Hospital of the University of Pennsylvania based on review of patient imaging and history at multidisciplinary Hepatic Tumor Conference at the Hospital of the University of Pennsylvania.
Age 18 years old
Albumin 2.4 g/dL; Total bilirubin 2 mg/dL; INR 1.5
Creatinine 2.0 mg/dL, AST 121 IU/L; ALT 189 IU/L
Child-Turcotte-Pugh Classification A or B
Eastern Clinical Oncology Group performance status 0 or1.

Exclusion Criteria:

Prior TACE
Active GI hemorrhage within 2 weeks of study enrollment
Ascites refractory to medical therapy
Contraindication to receiving HCQ or TACE
Unilobar HCC
Contraindication to contrast enhanced MRI (i.e. unable to undergo follow-up imaging)
Women who are pregnant
Participation in another concurrent treatment protocol
Intervention: Dexmedetomidine
Trial phase: Phase 4
ATC code: N05CM18
SMILES: Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 40
Group description: Standardized pre-op meds and spinal anesthetic.

Once the patient's spinal is performed, patient will receive the following:

Start with bolus of 0.5micrgram/kg over 10 minutes, and then infusion of 0.5 microgram/kg/hr Infusion will be stopped after the last staple or suture is performed on the incision.

Both groups will have a midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation.

Dexmedetomidine
Eligibility criteria:
Inclusion Criteria:

Total Knee arthroplasty American Society of Anesthesiologist score of 1-3 Age 18-85 Elective total knee arthroplasty under spinal anesthetic.

Exclusion Criteria:

Contraindication to Dexmedetomidine. (second or third degree heart block, renal or hepatic dysfunction) Contraindication to Spinal Anesthetic Pain being treated by opioids prior to operation Contraindication to premedication Previous total knee arthroplasty
Intervention: Ursodeoxycholic acid
Trial phase: Phase 2
ATC code: A05AA02
SMILES: [H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])CC[C@@]3(C)[C@@]([H])(CC[C@]3([H])[C@H](C)CCC(=O)O)[C@]1([H])[C@@H](O)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily

Ursodiol
Eligibility criteria:
Overweight or Obese subjects with BMI> 25 Kg/m2 with Type 2 Diabetes mellitus on Metformin, receiving standard of care for Type 2 DM. Otherwise individuals who are not currently on treatment for cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological, endocrine (other than T2DM) and unstable psychiatric disease.

Men or women. Women of childbearing potential will have a negative pregnancy test before initiation of medication.
Intervention: Ursodeoxycholic acid
Trial phase: Phase 2
ATC code: A05AA02
SMILES: [H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])CC[C@@]3(C)[C@@]([H])(CC[C@]3([H])[C@H](C)CCC(=O)O)[C@]1([H])[C@@H](O)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: matching placebo capsules to be taken twice daily

Ursodiol
Eligibility criteria:
Overweight or Obese subjects with BMI> 25 Kg/m2 with Type 2 Diabetes mellitus on Metformin, receiving standard of care for Type 2 DM. Otherwise individuals who are not currently on treatment for cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological, endocrine (other than T2DM) and unstable psychiatric disease.

Men or women. Women of childbearing potential will have a negative pregnancy test before initiation of medication.
Intervention: Guanfacine
Trial phase: Phase 2
ATC code: C02AC02
SMILES: N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 121
Group description: Guanfacine 6mg/day extended release

Guanfacine: 6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication.
Eligibility criteria:
Inclusion Criteria:

Age 18-65
Able to read, write and comprehend English
Smoker
Able to take oral medications and willing to adhere to a medication regimen
Provide evidence of a stable living residence in the last 2 months, have reasonable transportation to the study site, and have no plans to move within the next 3 months or unresolved legal problems

Exclusion Criteria:

Any significant current medical conditions that would contraindicate smoking
Current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) abuse or dependence of other substances, other than nicotine dependence or alcohol abuse
Positive test results at intake appointment on urine drug screen for illicit drugs
Past 30 days use of any psychoactive drugs including anxiolytics and antidepressants
Women who are pregnant or nursing
Suicidal, homicidal or evidence of current mental illness such as schizophrenia, bipolar disorder or major depression, or anxiety disorders
Meeting DSM-IV criteria for current attention deficit hyperactivity disorder (ADHD)
Individuals who are currently taking medications known to be effective for smoking cessation or are regular users of other tobacco products in the past 30 days
Only one member per household can participate in the study
Specific exclusions for administration of guanfacine not already specified include:
EKG evidence at baseline screening for any clinically significant conduction abnormalities or arrhythmias
Known intolerance for guanfacine or any alpha blocker
History of fainting, syncopal attacks
Heart failure or myocardial infarction
Impaired liver (as indicated by aspartate aminotransferase (AST), alanine aminotransferase (ALT) >3x normal)
Renal function (as indicated by estimated creatinine clearance <60cc/min)
Treatment with any antihypertensive drug or any alpha-adrenergic blocker
Use of any central nervous system depressant (e.g., phenothiazines, barbiturates, benzodiazepines)
Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin), or consumption of grapefruit juice
Subjects may not have donated blood in the past 8 weeks or have been involved in other investigational studies that involve substantial blood draws or medications unknown to us
Intervention: Hexose
Trial phase: Phase 4
ATC code: V04CE01 | V06DC01
SMILES: OCC1OC(O)C(O)C(O)C1O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5ml.

Glucose: An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
Eligibility criteria:
Inclusion Criteria:

females
with at least 10 cm from the lateral reticular veins of the leg or thigh of the leg
clinical classification of chronic venous disease C1(mild venous disease),
minimum age of 18 year-old and maximum age 69 year-old
agreement with the study
signing the free and informed consent ( IC)
not use anticoagulant drugs .

Exclusion Criteria:

male
varicose disease in any quantity or location with clinical classification of chronic venous disease different of C1(mild venous disease)
restrict mobility
arterial insufficiency
be allergic to any substance that may be related to the study drugs
any cause of dermatitis on application site
free of comorbidities clinically serious as diabetes mellitus, heart failure, respiratory failure, uncontrolled hypertension with medication, and uncontrolled hypothyroidism
pregnancy
previous deep vein thrombosis (DVT)
family history of DVT
thrombophilia
do not agree with the search terms
Intervention: Elocon
Trial phase: Phase 2
ATC code: D07AC13 | D07XC03 | R01AD09 | R03AK09 | R03BA07
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(OC(=O)c1ccco1)C(=O)CCl
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 35
Group description: 1 puff daily (220mcg) for 16 weeks
Eligibility criteria:
Inclusion Criteria:

Age 15 or older
Sever SCD phenotypes (Hb SS and Sβthalassemia0)
A positive response to cough/wheeze questions

Exclusion Criteria:

Patient carries a physician diagnosis of asthma
Patient is prescribed asthma medications
Patient is currently having a painful crisis (as defined by validated pain diary questions)
Patient has acute respiratory symptoms
Known hypersensitivity to milk proteins
Meets criteria for our operational diagnosis of asthma
More than 15 ED visits for pain over the preceding 12 months
Admitted or discharged from the hospital for SCD pain within the last 7 days
Intervention: Auranofin
Trial phase: Phase 2
ATC code: M01CB03
SMILES: CC(=O)OCC1OC([S-])C(OC(C)=O)C(OC(C)=O)C1OC(C)=O.CCP(CC)CC.[Au+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Patients receive auranofin PO on day 2.
Eligibility criteria:
Inclusion Criteria:

Absolute neutrophil count (ANC) >= 1500/mm^3
Platelet count (PLT) >= 100,000/mm^3
Creatinine =< 2 x upper limit of normal (ULN)
Either serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) or serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 1.5 x ULN
Total/direct bilirubin =< 1.5 x ULN
Alkaline phosphatase =< 1.5 x ULN
Hemoglobin >= 9 mg/dL
Negative urine or serum pregnancy test performed =< 7 days prior to registration, for women of childbearing potential only
Previously experienced paclitaxel induced pain during a current or past paclitaxel treatment that the treating healthcare provider thinks is consistent with the paclitaxel-induced acute pain syndrome; note: formal documentation of prior pain is not required
Scheduled to receive paclitaxel at a dose >= 70 mg/m^2 =< 14 days from randomization
Ability to complete the questionnaires or to do so with assistance

Exclusion Criteria:

Pregnant women
Nursing women
Any woman of childbearing potential or male partner of a woman of childbearing potential unwilling to employ acceptable contraception throughout the study and for at least 30 days after the last dose of the study drug
History of gold-induced disorders, including but not limited to, necrotizing enterocolitis, pulmonary fibrosis, exfoliative dermatitis, bone marrow aplasias or other severe hematologic disorders; history of severe allergic or anaphylactic reactions or hypersensitivity to auranofin or other gold compounds
Currently receiving Dilantin (phenytoin) or auranofin or another gold-containing compound
Anticipated use of filgrastim (G-CSF) or sargramostim (GM-CSF) within 30 days after receiving auranofin
Currently receiving immune-modulating therapies
Intervention: Dexmedetomidine
Trial phase: Not Applicable
ATC code: N05CM18
SMILES: Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 60
Group description: Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
Eligibility criteria:
Inclusion Criteria:

Subjects scheduled to undergo elective operation of TURBT on lateral wall for whom ONB was needed diagnosed through cystoscopy or CT examination preoperatively.
Subject's American Society of Anesthesiologists physical status is I-II.
The subject's parent/legally authorized guardian has given written informed consent to participate.

Exclusion Criteria:

Subject has a diagnosis of abnormal coagulation function.
Subject has a diagnosis of Diabetes mellitus.
Subject has a preexisting neurologic deficits of the lower extremities.
Subject has a history of alcohol or drug abuse.
Subject is pregnant or breast-feeding.
Subject is obese (body mass index >30kg/m2).
Intervention: Hydroxychloroquine
Trial phase: Not Applicable
ATC code: P01BA02
SMILES: CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 91
Group description: Hydroxychloroquine (HCQ) 200 mg. o.d. p.o. for two months.

Hydroxychloroquine (HCQ): Hydroxychloroquine (HCQ) 200 mg. oral, daily for two months.
Eligibility criteria:
Inclusion criteria:

Age greater than 18 years old and less than 50 years old
Uterus and cervix present
Willing to take daily acetylsalicylic acid or HCQ
Willing to undergo pelvic exams
In general good health, no chronic infection and not taking any anti-inflammatory or immunosuppressors
Being HIV negative
Without any cardiovascular disease
Being active in sex work (for the Female commercial sex worker group)

Exclusion criteria:

Age less than 18 years or more than 50 years old
Pregnancy (if a women becomes pregnant during the 10 weeks of the project she will be excluded)
Breast feeding
Pregnant in the last 12 months
Being positive for Sexual transmissible disease or bacterial vaginosis at week 0
Menopausal
No longer involve in sex work (for the female sex worker group)
Having a chronic disease
Taking any of the medication listed in annex 1 for health conditions
Being allergic to acetylsalicylic acid, other medication for pain or fever, tartrazine dye or chloroquine, hydroxuchloroquine, primaquine or any other medication
Having heartburn, stomach pain, stomach ulcer, anemia, hemophilia, kidney or liver disease, psoriasis, porphyria or other blood disease, G-6-PD deficiency, dermatitis (skin inflammation), alcoholism
Having experienced previous vision changes while taking chloroquine, hydroxychloroquine (Aralen) or primaquine.
Having a history of a diagnosed cardiovascular event, heart failure, peripheral arterial disease, angina, stoke, transient ischemic attack
Having a current or recurrent condition with a high risk of major bleeding
Having anemia

Current participation in a clinical trial

-

-
Intervention: Cytidine
Trial phase: Not Applicable
ATC code: L01BC01 | L01XY01
SMILES: Nc1ccn(C2OC(CO)C(O)C2O)c(=O)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Patients will receive 2 cycles of 1.5 grams/m2/day of intravenous cytarabine once daily for six consecutive days. Toxicity will be monitored through the duration of treatment. Observation will be complete upon count recovery and resolution of toxicity after the second cycle.

Cytosine Arabinoside
Eligibility criteria:
Inclusion Criteria:

Inclusion Criteria for Outpatient Administration of HiDAC

Unequivocal diagnosis of AML (>20% blasts in the bone marrow based on the WHO classification), excluding M3 (acute promyelocytic leukemia).
Documented complete remission (CR) following induction chemotherapy as defined as (18):
Bone marrow with <5% blasts; absence of blasts with Auer rods
Absolute neutrophil count >1000/mcL
Platelets >100,000/mcL
Independence of red cell transfusions
Absence of extramedullary disease
Age ≥ 55 years.
Relapsed AML patients are eligible as long as they meet other inclusion and exclusion criteria.
Good performance status of (ECOG 0-2), see appendix 15.3.
Adequate renal and hepatic function (Cr ≤ 1.2, alkaline phosphatase <3.0 x upper limit of normal, total bilirubin <1.5 x upper limit of normal unless there is a history of Gilbert's disease).

Inclusion Criteria for Quality of Life Comparison Group

All patients decline to participate as an out-patient or who are not eligible for participation in the out-patient portion of the study will be approached to participate in the QOL comparison.
Age ≥ 18 years

Exclusion Criteria:

Exclusion Criteria for All Patients

Active, uncontrolled viral, bacterial, or fungal infection.
Documented CNS leukemia.
If unable to do a reliable cerebellar examination for monitoring of neurotoxicity.
History of prior autologous or allogeneic bone marrow/stem cell transplant.
New York Heart Association class III/IV congestive heart failure, see appendix 15.4, or active ischemic heart disease.
Pregnant or lactating women (women and men of childbearing age should use effective contraception).
Concomitant active malignancy requiring treatment with cytotoxic chemotherapy or radiation therapy. (Ongoing hormonal therapy for the treatment of malignancy would not exclude patients from this trial.)
Time period of greater than 10 weeks between initiation of induction chemotherapy and day 1 of the first cycle of consolidation chemotherapy.
Patients seropositive for infection with Human Immunodeficiency Virus (HIV) are excluded due to potential for serious infectious complications associated with T-cell suppressive therapy in these patients.
Intervention: Cytidine
Trial phase: Not Applicable
ATC code: L01BC01 | L01XY01
SMILES: Nc1ccn(C2OC(CO)C(O)C2O)c(=O)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Patients receiving outpatient intravenous cytarabine will complete the EORTC QLQ-C30 quality of life form on the last day of each cycle of chemotherapy.

Cytosine Arabinoside
Eligibility criteria:
Inclusion Criteria:

Inclusion Criteria for Outpatient Administration of HiDAC

Unequivocal diagnosis of AML (>20% blasts in the bone marrow based on the WHO classification), excluding M3 (acute promyelocytic leukemia).
Documented complete remission (CR) following induction chemotherapy as defined as (18):
Bone marrow with <5% blasts; absence of blasts with Auer rods
Absolute neutrophil count >1000/mcL
Platelets >100,000/mcL
Independence of red cell transfusions
Absence of extramedullary disease
Age ≥ 55 years.
Relapsed AML patients are eligible as long as they meet other inclusion and exclusion criteria.
Good performance status of (ECOG 0-2), see appendix 15.3.
Adequate renal and hepatic function (Cr ≤ 1.2, alkaline phosphatase <3.0 x upper limit of normal, total bilirubin <1.5 x upper limit of normal unless there is a history of Gilbert's disease).

Inclusion Criteria for Quality of Life Comparison Group

All patients decline to participate as an out-patient or who are not eligible for participation in the out-patient portion of the study will be approached to participate in the QOL comparison.
Age ≥ 18 years

Exclusion Criteria:

Exclusion Criteria for All Patients

Active, uncontrolled viral, bacterial, or fungal infection.
Documented CNS leukemia.
If unable to do a reliable cerebellar examination for monitoring of neurotoxicity.
History of prior autologous or allogeneic bone marrow/stem cell transplant.
New York Heart Association class III/IV congestive heart failure, see appendix 15.4, or active ischemic heart disease.
Pregnant or lactating women (women and men of childbearing age should use effective contraception).
Concomitant active malignancy requiring treatment with cytotoxic chemotherapy or radiation therapy. (Ongoing hormonal therapy for the treatment of malignancy would not exclude patients from this trial.)
Time period of greater than 10 weeks between initiation of induction chemotherapy and day 1 of the first cycle of consolidation chemotherapy.
Patients seropositive for infection with Human Immunodeficiency Virus (HIV) are excluded due to potential for serious infectious complications associated with T-cell suppressive therapy in these patients.
Intervention: Dexmedetomidine
Trial phase: Not Applicable
ATC code: N05CM18
SMILES: Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 40
Group description: intranasal dexmedetomidine

Dexmedetomidine: intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
Eligibility criteria:
Inclusion Criteria:

Surgery:The laryngoscope vocal polyp excision
Aged 18 to 60 years old
Body mass index (BMI) < 30 kg/m2
American society of Anesthesiologist (ASA) I -II

Exclusion Criteria:

The investigator refused to participate
Known allergy or hypersensitive reaction to dexmedetomidine or anesthetic
With previous history of heart disease
Pregnant women; no reliable contraceptive measures in postmenopausal women
Preoperative heart rate less than 45bpm; Ⅱ or Ⅲ degree atrioventricular block; ischemic heart disease
Taking antihypertensive drugs such as methyldopa, clonidine and other α2 receptor agonist
Asthma
Sleep apnea syndrome
Liver and kidney dysfunction
Known to suffer from mental illness
Long-term use of sedatives and analgesics in patients
Intervention: Decitabine
Trial phase: Phase 1 | Phase 2
ATC code: L01BC08
SMILES: Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Ribavirin will be dosed from day 11-day 28 beginning with dose level 1 (1000mg orally twice daily). Number of patients with Dose Limiting Toxicities (DLT) at a given dose level is 0 of out of 3: enter 3 patients at the next dose level (dose Level 2- 1200mg orally twice daily; and then dose Level 3-1400 mg orally twice daily).(Arm B: For patients with morphologic M4/M5 subtypes).

Decitabine
Eligibility criteria:
Inclusion Criteria:

4.1.1 Age >/= 18 4.1.2 Diagnosis of AML according to World Health Organization (WHO) criteria except acute promyelocytic leukemia AND 4.1.3 Refractory AML defined as failure to achieve Complete Remission (CR) after 2 cycles of induction chemotherapy or persistence of > 40% bone marrow blasts after one cycle of chemotherapy induction OR 4.1.4 Relapsed AML defined as any evidence of disease recurrence after achieving a documented first or greater Complete Remission (CR) OR 4.1.5 Relapsed AML after stem cell transplantation. 90 days (since stem cell infusion) must have elapsed between transplant and emergence of recurrent AML OR 4.1.6 Newly diagnosed AML in a patient >65 years old not considered fit for standard 7+ 3 chemotherapy or who declines such therapy after discussion of therapeutic options available.

4.1.7 Eastern Cooperative Oncology Group (ECOG) performance status <3

Exclusion Criteria:

4.2.1 Abnormal renal function as evidenced by a calculated creatinine clearance ≤ 30 ml/min (Cockcroft-Gault formula (Appendix 2) 4.2.2 Abnormal liver function: Bilirubin >2.0 mg/dl, transaminase(s) more than 2.5x the upper limits of normal 4.2.3 Active systemic infection not responding to antibiotics 4.2.4 Known diagnosis of human immunodeficiency virus infection (HIV) 4.2.5 Patients who are post-allogeneic transplantation should not have active Graft vs. Host Disease (GVHD) greater than grade 1 of skin at time of enrollment. They may have had donor lymphocyte infusion (DLI) but not within 4 weeks of beginning the study.

4.2.6 Pregnant or breastfeeding female subjects 4.2.7 Known or suspected Central Nervous System (CNS) leukemia involvement; past involvement is not an exclusion.

-